Bulletin of the World Health Organization

Acute lower respiratory infections in childhood: opportunities for reducing the global burden through nutritional interventions

Daniel E Roth a, Laura E Caulfield a, Majid Ezzati b, Robert E Black a


Estimation of the global burden of child mortality attributable to undernutrition has played a crucial role in refocusing the attention of researchers and policy-makers on the importance of optimal maternal–child nutrition for promoting neonatal, infant and child survival,13 including the prevention of mortality due to severe acute lower respiratory infection (ALRI).25 To advance the public health application of knowledge about the interrelated burdens of childhood ALRI and poor nutrition in developing countries, we have critically reviewed available data regarding the efficacy and effectiveness of specific nutritional interventions for reducing global childhood ALRI incidence, morbidity and ALRI-specific mortality.


Search strategy

This review included meta-analyses and large-scale randomized controlled trials of micronutrient supplementation, breastfeeding promotion, complementary food provision or counselling, and antenatal nutritional interventions, in which at least one childhood ALRI outcome (incidence, morbidity or mortality) was measured. Smaller studies or those with non-randomized designs were included where higher-quality data were unavailable. The literature review was based primarily on several systematic reviews that formed the evidence base for the Lancet Undernutrition Series (LUS) published earlier this year (available at: http://www.globalnutritionseries.org/web_appendices). To include articles published after completion of the systematic reviews, we searched PubMed (1990–January 2008) and reference lists of selected recent articles published on each topic. PubMed search terms included nutrient-specific keyword(s) and a string that broadly captured childhood ALRI-related articles (“ALRI” OR “ARI” OR “pneumonia” OR “lower respiratory tract infection” OR “lower respiratory infection” OR “bronchiolitis” OR “bronchopneumonia” OR “morbidity” OR “mortality”) without age or language restrictions. Titles/abstracts were scanned for relevant interventional studies or key supportive articles, for which full-text articles were retrieved.

ALRI outcome definition

As there is no standard definition of childhood ALRI,6 studies were included if they applied an outcome definition incorporating at least one specific lower respiratory tract sign reported by a caregiver or study personnel (fast or difficulty breathing, chest wall indrawing) and/or abnormal auscultatory findings (crackles/crepitations or bronchial breath sounds). Authors occasionally differentiated ALRI subtypes on the basis of wheeze versus crepitations/crackles (probable bronchiolitis versus pneumonia, respectively); however, viral diagnostics, isolation of pathogenic bacteria from a sterile fluid (i.e. blood culture, lung aspirate), or unequivocal radiographic findings (i.e. lobar consolidation or pleural effusion) were not documented in the reviewed trials.

Burden of disease

Estimates of the burden of ALRI attributable to selected nutritional factors were extracted from an analysis performed for LUS3,7 [where “burden” refers to ALRI-related deaths and disability-adjusted life years (DALYs) lost], and are discussed in the context of related interventions. The ALRI-specific attributable fractions (Table 1) were not reported in LUS.


Breastfeeding promotion

A lack of exclusive breastfeeding in the first half of infancy is a risk factor for ALRI incidence, morbidity and death.3,5 In the LUS analysis,3 approximately 44% of infection-related neonatal deaths/DALYs (including those due to ALRI) and 20% of postnatal ALRI deaths/DALYs lost were attributed to suboptimal breastfeeding (Table 1). A causal effect of breastfeeding is plausible given the maternal–infant transfer of innate immune effectors (e.g. lactoferrin, lysozyme, secretory IgA, leukocytes)8 and influences of breast milk on immune-system maturation.9 Breastfeeding may enhance the antibody response to important pneumonia-causing pathogens (e.g. pneumococci, Haemophilus influenzae),10 but the specific mechanisms by which breastfeeding ameliorates ALRI resistance are less obvious than those that underlie diarrhoea risk reduction.

Eliminating the fraction of the ALRI burden due to suboptimal breastfeeding relies on effective breastfeeding promotion and education; however, few studies have quantified the effect of breastfeeding programmes on ALRI risk reduction.11 Four studies that reported respiratory outcomes did not distinguish upper and lower respiratory tract infections.1215 PROBIT, a large cluster-randomized trial of breastfeeding promotion (based on the WHO baby-friendly hospital initiative) in Belarus,16 was the only study from which an effect of breastfeeding promotion on ALRI outcomes could be inferred. Success of the promotion efforts was evidenced by increased breastfeeding continuation and a significant 40% decrease in diarrhoea incidence in the intervention group. The trial showed a 15% decrease in respiratory-disease-related hospitalizations (presumably due to ALRI), but despite the large sample size (n = 17 046) and high event rate (20.5% of infants in control arm had ≥ 1 respiratory disease hospitalization), the reported confidence intervals crossed the null after adjustment for confounders and design effects (Table 2).

The overall benefits of breastfeeding promotion are now widely accepted, and it seems doubtful that future similar trials will be deemed ethical or be more rigorously conducted than PROBIT, even though the magnitude of the effect might differ across populations or alternative behaviour-change strategies. Therefore, we concluded that the benefit of breastfeeding promotion on ALRI morbidity in PROBIT was consistent with observational data, and alongside the other known health benefits of breastfeeding (e.g. diarrhoea prevention, lactational amenorrhoea), reinforces the need to continue to support breastfeeding promotion policies and programmes in resource-poor settings.

Complementary food supplementation or counselling

A large body of literature has established strong links between malnutrition, immune dysfunction and infectious diseases.4,17,18 The LUS analysis estimated that one-quarter of under-five deaths and DALYs lost were attributable to undernutrition (represented by underweight or stunting) and could theoretically be prevented by dietary interventions that normalize anthropometric indices in early childhood (Table 1). These estimates suggest that in addition to an optimal prenatal environment and breastfeeding practices, improvements in the density, diversity and quality of complementary foods may reduce the risk of ALRI incidence or mortality. However, there is a surprising lack of intervention research addressing this question. We found only one study that measured the impact of complementary feeding education or food supplements on ALRI incidence,19 but the low statistical power limited interpretation of its null findings. There were also few published studies of the effect of comprehensive community-based nutrition programmes on ALRI outcomes. Two studies from Viet Nam reported ALRI outcomes,20,21 but interpretation of their findings was limited by methodological weaknesses (i.e. small sample size, quasi- or non-randomized designs, non-specific outcome ascertainment and incomplete presentation of findings).

Single micronutrient interventions

Vitamin A

Vitamin A is involved in immune function and respiratory epithelial cell differentiation,22 yet the impact of high-dose supplementation on under-five mortality cannot be accounted for by its effects on ALRI outcomes. A rigorous meta-analysis of five large trials concluded that routine vitamin A supplementation did not affect ALRI incidence or mortality (Table 2),23 inferences that have not changed over time.24 Estimates of the effect of routine early neonatal vitamin A supplementation remain imprecise and inconsistent,2527 and await clarification by as-yet unpublished findings from a large study of early neonatal vitamin A supplementation in Bangladesh. In the treatment setting, infants and children with non-measles-related ALRI do not benefit from adjunctive high-dose vitamin A administration.24,28,29

Iron and folic acid

The interplay between iron and infection has been the subject of enduring debate in nutritional immunology, primarily because iron deficiency impairs components of cell-mediated immunity but can also inhibit the growth of bacterial pathogens.30 Nonetheless, the epidemiological data regarding the effect of iron supplementation on ALRI incidence quite convincingly reveal its effect to be null (Table 2).31,32

A recent prospective study in India found serum folate status to be independently associated with the risk of ALRI,33 but we did not identify any trials assessing the effect of folic acid supplementation alone on ALRI outcomes. However, in a large trial in Nepal, the combination of daily iron and folic acid (IFA) supplementation modestly reduced ALRI incidence and mortality compared to placebo (Table 2).34 Given the lack of effect of iron supplementation alone and biological mechanisms by which folates may be implicated in immune function,35 the benefit may have been attributable to improvements in folate status; however, the wide confidence intervals that included the null indicate that the observation requires confirmation.

Vitamin D and calcium

Nutritional rickets, caused by dietary deficiencies of vitamin D and/or calcium, has been strongly associated with severe ALRI in hospitalized children in some settings.36,37 Case-control studies in developing countries have found low vitamin D status to be associated with the risk of ALRI in Indian children38 and Turkish neonates,39 but not with the risk of viral bronchiolitis in young Canadian children.40 The active form of vitamin D affects a variety of immune functions,35 including the synthesis of endogenous antimicrobial peptides.41 However, interventional trials of the effect of maternal or infant supplementation with vitamin D, with or without calcium, on the incidence of infant ALRI have not yet been reported.


Infant and child zinc supplementation has been intensively studied because dietary zinc deficiency is highly prevalent in developing countries42 and zinc is involved in the maintenance of skin and mucous membranes, leukocyte function and cytokine expression.43 A recent meta-analysis of randomized efficacy trials conducted in South Asia confirmed that routine oral daily or weekly zinc supplementation for at least 3 months significantly reduces the incidence of childhood ALRI (Table 2),44 an effect that may be specific to non-wheezy ALRI (i.e. cases that are more likely to be pneumonia than viral bronchiolitis);45 this effect appears to increase with greater severity of disease,45 and was not evident in infants less than 6 months of age.46

Several studies not included in the published meta-analysis have shown null or non-significant effects of routine zinc on ALRI incidence in Latin America,47,48 South Africa49 and Nepal.50 Although it is possible that the heterogeneity is due to characteristics of the study populations, it is notable that ALRI was ascertained on the basis of either maternal report or WHO criteria alone (elevated respiratory rate) in these null studies. In an updated meta-analysis of routine zinc supplementation trials, we found that incidence of ALRI was substantially reduced by zinc supplementation when the diagnosis was established by active prospective case-finding and a clinical exam that included pulmonary auscultation (relative rate, RR 0.78; 95% confidence interval, CI: 0.68–0.91; based on three of the four trials included in the published meta-analysis), whereas the effect was absent in trials that ascertained ALRI on the basis of either elevated respiratory rate alone (RR 0.99; 95% CI: 0.89–1.09) or caregiver recall of ALRI signs or symptoms (RR 1.02; 95% CI: 0.97–1.09) (Roth & Black, unpublished findings). Null findings may thus be biased due to non-specific outcome definitions51 or “contamination” by episodes of upper respiratory tract infections.

If the magnitude of the benefit of zinc prophylaxis on ALRI incidence is limited to bacterial pneumonia or increases with greater disease severity,45 a large relative decrease in ALRI-specific mortality would be expected; however, the estimated reduction upon pooling available data for children aged 1–59 months was only 15% (Table 2).3 The discrepancy could be purely methodological (i.e. misclassification of causes of death), or perhaps reflects the failure of zinc to prevent disease in those children with the highest baseline risk of ALRI fatality (i.e. young infants). An alternative explanation is that zinc supplements may increase the case fatality rate in a small subset of children who acquire ALRIs of certain bacterial etiologies, as suggested by Coles et al. who hypothesized that specific zinc–pathogen interactions may deleteriously alter the host response in severe pneumonia.52

In summary, routine zinc supplementation to young children prevents about one-quarter of ALRI cases, which likely translates into a modest reduction in ALRI-related mortality. Scaling-up zinc supplementation to all regions with high prevalence of zinc deficiency could avert an estimated 7% of ALRI deaths and DALYs lost (Table 1).

In contrast to its prophylactic effect, there is no strong evidence of a benefit of zinc supplementation in the treatment context. Of three published randomized controlled trials evaluating zinc supplementation as adjunctive treatment in children presenting to hospital with ALRIs, one found a relative reduction in the duration of severe disease equivalent to about one day in hospital,53 one study showed no benefit,54 and a third study found that zinc caused a slightly reduced duration of fever and severe illness in boys, but not in girls.55

Multiple micronutrient interventions

Children in resource-poor settings often exhibit concurrent deficiencies of multiple micronutrients,56 many of which function as cofactors or regulatory molecules in immune or inflammatory cascades (e.g. vitamins C, D, selenium).35 Therefore, multiple micronutrient supplements may theoretically augment the effect of zinc on infectious disease resistance in resource-poor settings.

Addition of zinc to IFA supplementation

Routine infant/child IFA supplementation is currently recommended by WHO for regions with a high prevalence of iron-deficiency anaemia,57 so it is of primary interest to know whether including zinc in a daily IFA regimen would reduce ALRI-associated morbidity or mortality. In a large factorial trial in Nepal, zinc minimally strengthened the effect of IFA on ALRI incidence and mortality relative to placebo (Table 2);34 however, in the United Republic of Tanzania, the addition of zinc to IFA did not notably alter the risk of non-malarial infection-related adverse events (hospitalization or death) compared to placebo.58 In a third study involving children aged 1–23 months in Delhi (n = 94 359), but in which a placebo arm was not included, adding zinc to routine daily IFA supplementation for up to 12 months did not significantly impact the risk of ALRI-related hospitalizations (RR 1.09; 95% CI: 0.94–1.25) compared to IFA alone.59 In the latter trial, adding zinc was associated with reduced ALRI-related mortality (RR 0.73; 95% CI: 0.55–0.96; confidence limits unadjusted for the likely negligible effect of intrahousehold clustering), but the authors emphasized that overall mortality and the distribution of causes of death did not significantly differ between the IFA + zinc and IFA-treatment arms, suggesting this estimate should be interpreted with caution.

Multiple micronutrient supplements or fortificants

In a recent trial involving children aged 1–3 years in Delhi, India, a commercial milk powder fortified with additional vitamins A, C, E, iron, zinc (7.8 mg more than control group), selenium and copper led to a significant reduction in the incidence of clinically confirmed ALRI compared to the standard milk powder (Table 2).60 Three other studies of multiple micronutrient supplements or fortificants had null results but were inadequately powered to detect moderate differences in ALRI incidence between treatment and control arms.49,61,62

In summary, the only multiple micronutrient intervention with a clear benefit on ALRI incidence or mortality was a milk powder fortified with zinc and six other micronutrients, but the effect size was comparable to that achieved by supplementation with zinc alone. Null findings in trials using non-food-based supplements that combined iron and zinc (i.e. attenuation of the expected zinc effect) may be partially attributable to the inhibitory effects of supplemental iron on absorption of zinc supplements.63 Where food fortification is not feasible, a proposed approach to avoid intraintestinal mineral interactions is alternate-day zinc and iron supplementation.

Antenatal nutritional interventions

Low birth weight (LBW: birth weight < 2500 g) in term-infants is a surrogate marker of intrauterine growth restriction (IUGR) and an established epidemiological risk factor for ALRI incidence and hospitalization.5 In the LUS analysis,3 an estimated 17.6% of ALRI-related deaths and DALYs lost in term neonates (birth to 1 month of age) were attributable to LBW (Table 1).

The biological plausibility of the association between LBW and respiratory morbidity is supported by observations of impaired immunocompetence in infants born small-for-gestational6466 and the association of fetal growth restriction with structural alterations that may affect lung anatomy and function.6769 However, the causal nature of the association between LBW and ALRI is complex, particularly given that LBW represents the cumulative and aggregative effect of a range of nutritional and non-nutritional prenatal exposures.70,71 Wilcox72 and others73 have persuasively questioned the use of LBW as a biomarker of the effect of antenatal exposures on neonatal morbidity and mortality, suggesting it is of more practical relevance to directly consider the modifiable maternal nutritional and dietary factors that are hypothesized to “programme” the fetal immune system.9 Unfortunately, at present there are insufficient data to recommend antenatal nutritional interventions on the basis of their effects on infant ALRI outcomes. Trials of antenatal zinc,74 multiple micronutrients75 and vitamin A76 did not have statistically significant impacts, but may have lacked sufficient power to demonstrate subtle, but potentially meaningful, effects.


Observational evidence of an association between inadequate growth and the risk of experiencing or dying from ALRI in early childhood is strong and consistent,2,3,5 suggesting there could be a potentially large impact of nutritional interventions on ALRI morbidity and mortality. However, evidence-based public health policy and practice ideally rely on efficacy and effectiveness data from well conducted trials.

Based on a critical review of the literature, we were able to reach conclusions about only a few of the potential nutritional interventions. First, oral zinc supplementation in children > 6 months of age was the only intervention for which high-quality trial evidence has demonstrated a significant reduction in childhood ALRI incidence and a trend towards a reduction in mortality. Important feasibility issues remain to be resolved, including attenuation of the effects by concurrent iron supplementation, potential effects on case-fatality due to ALRIs of specific etiologies, and the optimal mode of community-based delivery (i.e. fortification, supplementation). Large-scale cluster-randomized effectiveness trials in Bangladesh77 and India78 have demonstrated that programmatic implementation of the WHO recommendation to incorporate a two-week course of zinc supplementation into case management algorithms for children with acute gastroenteritis has the added benefit of reducing the burden of severe ALRI in the community. Scale-up of this approach is therefore suggested as a feasible and effective strategy for improving zinc status in at-risk populations.

Second, despite the limited available trial data, there should be little hesitation in including ALRI risk reduction in the list of benefits of exclusive breastfeeding, given the strength and consistency of observational findings and the evidence of a modest reduction in ALRI-related hospitalizations in the only rigorous trial of breastfeeding promotion. Third, there was strong evidence that vitamin A supplementation (after the neonatal period), or iron supplementation alone, do not reduce the risk of ALRI incidence or mortality.

We found insufficient evidence of efficacy of other specific nutritional interventions for ALRI risk reduction. However, the strength of the association between anthropometric indices and ALRI mortality suggests that a range of interventions (not limited to dietary changes) that reduce the prevalence of LBW, underweight or stunting79 would be expected to consequentially diminish the burden of ALRI. Rigorous assessments of the effect on ALRI outcomes of improved feeding practices or comprehensive nutrition education programmes should be considered, since multicomponent interventions are most likely to improve overall nutritional status. In future trials, two major methodological issues need to be addressed. First, non-specific outcome ascertainment based on maternal recall or WHO criteria alone may nullify true effects, strongly suggesting that lower respiratory tract morbidity be prospectively assessed by active case-finding and clinical criteria. Second, trials need to have adequate power to detect meaningful intergroup differences in ALRI incidence. Even if a relatively large effect size is expected (e.g. hazard ratio = 0.7), over 800 child-years of follow-up are required in each group (e.g. 800 children treated and monitored for one year), under optimal conditions of a high baseline incidence rate (i.e. 0.3 episodes per child-year), minimal loss to follow-up, and conventional statistical assumptions (i.e. 5% risk of type I error, 80% power). Sufficient sample sizes are of particular importance in trials of multiple micronutrient supplements, food fortification or integrated nutrition programmes, because these trials cannot readily be pooled post-hoc due to non-uniformity of the interventions. The logistical, ethical and financial challenges of conducting large trials with active surveillance emphasizes the importance of building a strong scientific rationale for testing a specific nutritional intervention,80 based on translational research (e.g. effects on immune function biomarkers), preliminary dose-finding trials (e.g. efficacy in improving biomarkers of micronutrient status), and qualitative feasibility studies (i.e. to establish that the intervention is acceptable to communities and could reasonably be scaled-up if shown to be effective).


As with other interventions to prevent ALRI discussed elsewhere in this issue of the Bulletin, nutritional interventions such as micronutrient supplementation or breastfeeding promotion can have a broad range of child health benefits.79 Implementation and rigorous evaluation of multicomponent nutritional intervention programmes should be a high priority – to reduce the incidence and mortality associated with severe ALRI, as well as the overall disease burden that persists among children in developing countries. ■


We thank the authors of the Lancet Undernutrition Series papers for their contribution to the burden of disease estimates, WHO and others for the development of prevalence estimates for the risk factors, the scientists who provided their data for use in pooled analyses, those who conducted the pooled analyses to develop risk estimates, and Rodrigo Dias at the Harvard Initiative for Global Health, who assisted with calculating the burden of nutrition risk factors.

Competing interests: None declared.



  • Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD, United States of America.
  • Department of Population and International Health and Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA.